Breaking News
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - High diet quality associated with lower risk of death in colorectal cancer patients
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - Research provides insight into neurobiology of aggression and bullying
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
Newer Epilepsy Drugs Haven’t Boosted Seizure Control

Newer Epilepsy Drugs Haven’t Boosted Seizure Control

image_pdfDownload PDFimage_print

Action Points

  • Despite the arrival of newer anti-epileptic drugs (AEDs), seizure control hasn’t improved in the last several decades.
  • The study finding suggests that the modern AEDs are seizure-suppressing and not disease-modifying, and do not alter the underlying cause for the seizures.

Despite the arrival of newer anti-epileptic drugs (AEDs), seizure control hasn’t improved in the last several decades, researchers found.

In a large longitudinal cohort study in Scotland, the 1-year seizure-free rate was unchanged over the study period of 1982 to 2012, hovering in the low 60% range, reported Patrick Kwan, MD, PhD, of Royal Melbourne Hospital in Australia, and colleagues.

That means more than a third of epilepsy patients still won’t have adequate seizure control: “Despite the availability of many new AEDs with differing mechanisms of action, overall outcomes in newly diagnosed epilepsy have not improved,” they wrote online in JAMA Neurology.

In 2000, this same research group published outcomes for patients treated from 1982 to 1998, showing that more than a third of epilepsy patients remained uncontrolled. They also found several predictors of poor treatment response, including unknown disease etiology, a high number of seizures before starting therapy, longer duration of epilepsy before the first treatment, history of recreational drug use, family history of epilepsy, history of psychiatric disease, and history of febrile seizures — all of which were again confirmed to predict poor response in this extended version of the study, they said.

More than a dozen new AEDs with different mechanisms of action have come on the market since the earlier study was published, and while some have touted improved safety, all have been reported to have similar efficacy to established AEDs.

For the latest study, Kwan’s group looked at data on 1,795 patients newly treated for epilepsy at Western Infirmary in Glasgow, Scotland, from July 1, 1982 to Oct. 31, 2012. All were followed for a minimum of 2 years (the median follow-up was 11 years) and their median age was 33.

At the end of the study, about 64% had been seizure-free for at least a year, and the proportion of patients who were seizure-free at last follow-up was similar across the three time period subgroups, ranging from 61% to 64%, they reported.

Among those achieving 1-year seizure freedom, 87% were taking monotherapy and 90% achieved seizure control with the first or second AED regimens.

Overall, about half of patients remained seizure-free for at least a year with the initial AED, but if this drug failed, the second and third regimens provided only an additional 12% and 4% likelihood of seizure freedom, respectively. Only 2% of patients achieved optimal seizure control with subsequent AEDs, they reported.

Those with epilepsy that wasn’t controlled with the first AED had a greater likelihood of not responding to treatment for each subsequent medication (OR 1.73, 95% CI 1.56 to 1.91, P<0.001) -- lending support to the definition of drug-resistant epilepsy as "failure of two appropriately selected and tolerated AED regimens," they wrote.

Throughout the trial, there was a marked increase in the use of newer AEDs: the first decade was dominated by carbamazepine, valproate, and phenytoin as initial therapy, while the latter decade was dominated by valproate, levetiracetam, and lamotrigine as initial monotherapy.

“While some modern AEDs have novel anti-seizure mechanisms, their increasing use did not seem to have improved overall long-term seizure control,” the authors wrote. “This may be attributed to deficiencies in the preclinical and clinical strategies of AED development,” such as enrollees being required to have established epilepsy and a high frequency of seizures.

“This finding also suggests that the modern AEDs still lack the capacity to rectify the underlying neuropathological processes and reverse epileptogenesis,” they continued. “Our results provide further evidence that current AEDs are seizure-suppressing and not disease-modifying. Future research should focus on novel treatments that can modify the development or progression of epilepsy, ideally guided by biomarkers.”

In an accompanying editorial, Allen Hauser, MD, of Columbia University in New York City, called the findings “sobering and somewhat disconcerting.”

“The results of this study suggest that the advent of new pharmacological therapies has had little impact on the proportion of newly diagnosed people rendered seizure-free” — a finding that “is not new and should not be surprising.”

Even with the best management, Hauser wrote, “only about two-thirds of people with newly diagnosed epilepsy will be successfully treated … Resources need to be dedicated to developing anti-epilepsy therapies that interfere with or reverse the underlying disease process, rather than merely identifying agents that suppress seizures.”

Kwan and co-authors disclosed relevant relationships with Eisai, UCB Pharma, GlaxoSmithKline, Lundbeck, Bial, GW Pharmaceuticals, Takeda, Sanofi, Abbott, AbbVie, AstraZeneca, Amgen, Johnson & Johnson, and Pfizer.

Hauser disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-27T09:30:00-0500

Tagged with:

About author

Related Articles